vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and CATHAY GENERAL BANCORP (CATY). Click either name above to swap in a different company.
CATHAY GENERAL BANCORP is the larger business by last-quarter revenue ($222.8M vs $139.2M, roughly 1.6× ADMA BIOLOGICS, INC.). CATHAY GENERAL BANCORP runs the higher net margin — 653.4% vs 35.5%, a 617.9% gap on every dollar of revenue. On growth, CATHAY GENERAL BANCORP posted the faster year-over-year revenue change (19.5% vs 18.4%). CATHAY GENERAL BANCORP produced more free cash flow last quarter ($363.7M vs $34.6M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 12.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Cathay General Bancorp is a U.S.-headquartered bank holding company that operates Cathay Bank, offering full-spectrum commercial and personal banking services. It primarily serves Asian American communities and small-to-medium enterprises across major U.S. states including California, New York and Texas, as well as select Asian markets, with products covering deposits, loans, and wealth management solutions.
ADMA vs CATY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $222.8M |
| Net Profit | $49.4M | $90.5M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 50.9% |
| Net Margin | 35.5% | 653.4% |
| Revenue YoY | 18.4% | 19.5% |
| Net Profit YoY | -55.9% | 12.9% |
| EPS (diluted) | $0.20 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $222.8M | ||
| Q3 25 | $134.2M | $210.6M | ||
| Q2 25 | $122.0M | $196.6M | ||
| Q1 25 | $114.8M | $187.8M | ||
| Q4 24 | $117.5M | $186.5M | ||
| Q3 24 | $119.8M | $189.5M | ||
| Q2 24 | $107.2M | $178.5M | ||
| Q1 24 | $81.9M | $175.2M |
| Q4 25 | $49.4M | $90.5M | ||
| Q3 25 | $36.4M | $77.7M | ||
| Q2 25 | $34.2M | $77.5M | ||
| Q1 25 | $26.9M | $69.5M | ||
| Q4 24 | $111.9M | $80.2M | ||
| Q3 24 | $35.9M | $67.5M | ||
| Q2 24 | $32.1M | $66.8M | ||
| Q1 24 | $17.8M | $71.4M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 50.9% | ||
| Q3 25 | 38.0% | 44.5% | ||
| Q2 25 | 35.1% | 49.0% | ||
| Q1 25 | 30.4% | 46.1% | ||
| Q4 24 | 32.6% | 46.5% | ||
| Q3 24 | 33.1% | 41.2% | ||
| Q2 24 | 36.6% | 40.7% | ||
| Q1 24 | 26.7% | 45.7% |
| Q4 25 | 35.5% | 653.4% | ||
| Q3 25 | 27.1% | 36.9% | ||
| Q2 25 | 28.1% | 39.4% | ||
| Q1 25 | 23.4% | 37.0% | ||
| Q4 24 | 95.2% | 587.9% | ||
| Q3 24 | 30.0% | 35.6% | ||
| Q2 24 | 29.9% | 37.4% | ||
| Q1 24 | 21.7% | 40.8% |
| Q4 25 | $0.20 | $1.33 | ||
| Q3 25 | $0.15 | $1.13 | ||
| Q2 25 | $0.14 | $1.10 | ||
| Q1 25 | $0.11 | $0.98 | ||
| Q4 24 | $0.45 | $1.11 | ||
| Q3 24 | $0.15 | $0.94 | ||
| Q2 24 | $0.13 | $0.92 | ||
| Q1 24 | $0.08 | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | — |
| Total DebtLower is stronger | $72.1M | $119.1M |
| Stockholders' EquityBook value | $477.3M | $2.9B |
| Total Assets | $624.2M | $24.2B |
| Debt / EquityLower = less leverage | 0.15× | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — | ||
| Q1 24 | $45.3M | — |
| Q4 25 | $72.1M | $119.1M | ||
| Q3 25 | $72.4M | $119.1M | ||
| Q2 25 | — | $119.1M | ||
| Q1 25 | — | $119.1M | ||
| Q4 24 | $72.3M | $119.1M | ||
| Q3 24 | — | $119.1M | ||
| Q2 24 | — | $119.1M | ||
| Q1 24 | — | $119.1M |
| Q4 25 | $477.3M | $2.9B | ||
| Q3 25 | $431.2M | $2.9B | ||
| Q2 25 | $398.3M | $2.9B | ||
| Q1 25 | $373.4M | $2.9B | ||
| Q4 24 | $349.0M | $2.8B | ||
| Q3 24 | $231.9M | $2.8B | ||
| Q2 24 | $188.3M | $2.8B | ||
| Q1 24 | $153.7M | $2.8B |
| Q4 25 | $624.2M | $24.2B | ||
| Q3 25 | $568.7M | $24.1B | ||
| Q2 25 | $558.4M | $23.7B | ||
| Q1 25 | $510.6M | $23.2B | ||
| Q4 24 | $488.7M | $23.1B | ||
| Q3 24 | $390.6M | $23.3B | ||
| Q2 24 | $376.4M | $23.2B | ||
| Q1 24 | $350.9M | $23.4B |
| Q4 25 | 0.15× | 0.04× | ||
| Q3 25 | 0.17× | 0.04× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | 0.21× | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $368.6M |
| Free Cash FlowOCF − Capex | $34.6M | $363.7M |
| FCF MarginFCF / Revenue | 24.8% | 163.2% |
| Capex IntensityCapex / Revenue | 0.8% | 2.2% |
| Cash ConversionOCF / Net Profit | 0.72× | 4.07× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $672.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $368.6M | ||
| Q3 25 | $13.3M | $150.6M | ||
| Q2 25 | $21.1M | $64.0M | ||
| Q1 25 | $-19.7M | $99.0M | ||
| Q4 24 | $50.2M | $329.2M | ||
| Q3 24 | $25.0M | $81.2M | ||
| Q2 24 | $45.6M | $72.9M | ||
| Q1 24 | $-2.2M | $88.2M |
| Q4 25 | $34.6M | $363.7M | ||
| Q3 25 | $-1.1M | $150.1M | ||
| Q2 25 | $18.7M | $62.7M | ||
| Q1 25 | $-24.4M | $96.3M | ||
| Q4 24 | $47.5M | $325.5M | ||
| Q3 24 | $24.0M | $80.0M | ||
| Q2 24 | $43.6M | $72.4M | ||
| Q1 24 | $-4.6M | $87.3M |
| Q4 25 | 24.8% | 163.2% | ||
| Q3 25 | -0.8% | 71.3% | ||
| Q2 25 | 15.3% | 31.9% | ||
| Q1 25 | -21.2% | 51.2% | ||
| Q4 24 | 40.4% | 174.6% | ||
| Q3 24 | 20.0% | 42.2% | ||
| Q2 24 | 40.7% | 40.5% | ||
| Q1 24 | -5.6% | 49.8% |
| Q4 25 | 0.8% | 2.2% | ||
| Q3 25 | 10.7% | 0.2% | ||
| Q2 25 | 2.0% | 0.6% | ||
| Q1 25 | 4.1% | 1.4% | ||
| Q4 24 | 2.3% | 1.9% | ||
| Q3 24 | 0.9% | 0.6% | ||
| Q2 24 | 1.9% | 0.3% | ||
| Q1 24 | 2.9% | 0.5% |
| Q4 25 | 0.72× | 4.07× | ||
| Q3 25 | 0.36× | 1.94× | ||
| Q2 25 | 0.62× | 0.83× | ||
| Q1 25 | -0.73× | 1.42× | ||
| Q4 24 | 0.45× | 4.10× | ||
| Q3 24 | 0.70× | 1.20× | ||
| Q2 24 | 1.42× | 1.09× | ||
| Q1 24 | -0.12× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CATY
Segment breakdown not available.
